← Back to Search

Radiopharmaceutical

(99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose) for Lung Cancer

Phase 3
Waitlist Available
Research Sponsored by Cell>Point LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from 99m-tc-ec-dg injection up to 90 days post-injection
Awards & highlights

Study Summary

This trial is looking at whether a different imaging scan can provide the same information as the current standard scan for lung cancer.

Eligible Conditions
  • Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from 99m-tc-ec-dg injection up to 90 days post-injection
This trial's timeline: 3 weeks for screening, Varies for treatment, and from 99m-tc-ec-dg injection up to 90 days post-injection for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Efficacy:Comparison of 99mTc-EcC-DG SPECT/CT images to 18F-FDG PET/CT images of primary lung cancer lesion and metastatic lesions
Secondary outcome measures
Safety:Through Adverse Event Collection

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: 99m Tc-EC-DG imaging agentExperimental Treatment1 Intervention
99m Tc-EC-DG injection followed by SPECT/CT imaging (target of 20-30 mCi of Tc)and < 1 mg EC-DG
Group II: 18-F-FDG Imaging AgentActive Control1 Intervention
18 F FDG followed by PET/CT imaging

Find a Location

Who is running the clinical trial?

Cell>Point LLCLead Sponsor
4 Previous Clinical Trials
88 Total Patients Enrolled
Cynthia Phurrough, BSStudy DirectorConsultanat

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has (99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose) been cleared by the FDA?

"(99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)'s Phase 3 status means that there is both safety and efficacy data supporting its use. This, in turn, gives it a score of 3."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer
2020. "A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01394679.
All > Lung
~36 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top